FilingSEC EDGAR6-K
BrainsWay Reports Pilot Study Results for Depression and Alzheimer's
· SEC accepted
StagePilot Study
Filing content
BrainsWay announced positive pilot study results for its Deep TMS technology in patients with depression and early-stage Alzheimer's, showing an 83.3% response rate and 50% remission rate.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…